Predictive markers of immune checkpoint inhibitors

Wei-ran XU,Jun LIANG

DOI: https://doi.org/10.16073/j.cnki.cjcpt.2017.13.013

2017-01-01

Abstract:OBJECTIVE For the past few years,the checkpoint inhibitors,such as PD-1 inhibitors and CTLA-4 in-hibitors,demonstrated an advantage in terms of the survival of melanoma and lung cancer patients with the development of novel immunotherapy agents.Thus,exploring predictive biomarkers may contribute to the screening the target population for immune checkpoint inhibitors and promoting the development of individualized precision therapy in advanced cancer. This article induced the progress about the predictive biomarkers of checkpoint inhibitors,providing a theoretical basis for the precision medicine study of immunotherapy.METHODS Based on Pubmed and CNKI database,by using "immune checkpoint inhibitors,biomarker,prognosis"as key words to trace related papers from 1995-10 to 2017-02.Inclusion crite-ria were as follows:the definition of immune checkpoint inhibitors;the mechanism of immune checkpoint inhibitors;the predictive factors of immune checkpoint inhibitors.Exclusion criteria:(1)Those exists problems in research designs or sta-tistical methods.(2)those has incomplete data or unclear results.Totally 44 papers (2 chinese literatures)were finally in-cluded for analysis.RESULTS The immune checkpoint inhibitors work specifically on the body's immune system to en-hance the antitumor activity of various immune cells.It is relatively slower to take effects.However,once the effects ap-pear,it will last for a very long period.Selecting the appropriate predictive factors and screening the target population be-fore the treatment plays a very important role for clinical choice.It has been proved that the expression rate of PD-L1,mi-crosatellite instability and tumor mutation burden are correlated with the treatment effects of immune checkpoint inhibi-tors.The significance of other biomarkers need further investigation.CONCLUSION The expression rate of PD-L1, microsatellite instability and tumor mutation burden were reliable predictive biomarkers for the treatment effects of im-mune checkpoint inhibitors.